Edgewise Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 9, 2024. Edgewise is a clinical-stage biopharmaceutical company developing treatments for severe muscle diseases. It has no approved products and has not generated revenue.
Business context and programs
- Sevasemten (EDG-5506): Lead candidate for dystrophinopathies. The company reported four ongoing Phase 2 trials and a potentially registrational Becker muscular dystrophy cohort, GRAND CANYON.
- EDG-7500: Candidate for hypertrophic cardiomyopathy. It was in Phase 1 development during the quarter; the filing says a Phase 2 study began in April 2024.
- The company also has preclinical discovery programs, including EDG-003. It reported 92 full-time employees at March 31, 2024.
Financial results and liquidity
Amounts below are in millions, except per-share data. Operating margins are not meaningful because the company reported no revenue.
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | None | None | No product revenue to date |
| Research and development expense | $27.7 | $19.9 | +$7.8 |
| General and administrative expense | $7.1 | $5.8 | +$1.2 |
| Total operating expenses | $34.8 | $25.7 | +$9.0 |
| Interest income | $6.2 | $2.9 | +$3.4 |
| Net loss | $28.5 | $22.8 | Loss increased $5.7 |
| Net loss per share, basic and diluted | $0.33 | $0.36 | Lower loss per share |
| Cash used in operating activities | $28.6 | $22.8 | Use increased $5.8 |
- Research and development expense rose 39%, mainly from increased sevasemten trial and manufacturing activity, new EDG-7500 clinical costs, and higher personnel costs. G&A expense rose 21%, primarily from personnel-related costs.
- Cash, cash equivalents and marketable securities totaled $532.8 million at March 31, versus $318.4 million at December 31, 2023. Cash and cash equivalents alone were $30.3 million; most liquidity was in marketable securities.
- Current assets were $541.4 million and current liabilities $14.6 million. Total liabilities were $18.9 million, including $5.2 million of operating lease liabilities. The filing reports no borrowings.
- Cash flows: operating activities used $28.6 million; investing activities used $268.3 million, primarily reflecting purchases of marketable securities; financing activities provided $241.1 million, principally from equity offerings and option exercises.
- The January 2024 registered direct offering raised $240.0 million gross and $231.9 million net. The company also received approximately $7.0 million from its ATM program before suspending it. Shares issued and outstanding increased to 93.3 million from 70.5 million at year-end.
Changes, outlook, risks and notable items
- Management expects significant losses and rising research and development costs as trials advance. It says existing cash, cash equivalents and marketable securities are expected to fund operations and capital needs for at least 12 months from issuance of the financial statements; the company expects to need substantial additional capital over time.
- On April 15, 2024, after quarter-end, Edgewise announced positive two-year topline results from the open-label ARCH sevasemten trial in adults with Becker muscular dystrophy. The filing cautions that preliminary or topline results may change following further data review and verification.
- Key risks include clinical-trial safety, efficacy, enrollment and timing; dependence on sevasemten; reliance on third parties for clinical trials and manufacturing; competition; intellectual-property challenges; and the possibility that future financing may dilute shareholders or be unavailable on acceptable terms.
- The company reported no material pending or threatened legal proceedings. Management concluded disclosure controls and procedures were effective at a reasonable-assurance level, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress, enrollment, endpoints and subsequent data updates for GRAND CANYON and the other sevasemten trials, including the final interpretation of ARCH results.
- EDG-7500 Phase 2 trial progress and the timing and cost of advancing both clinical programs.
- Cash burn and runway assumptions as research, clinical-trial and manufacturing spending increase.
- Share dilution from the January offering, ATM sales and potential future equity or debt financing.
- Manufacturing supply continuity, clinical safety findings and competitive developments in muscular dystrophy and hypertrophic cardiomyopathy.